ArticleJournal of virology2017
The Envelope Gene of Transmitted HIV-1 Resists a Late Interferon Gamma-Induced Block.
Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Obstructive sleep apnea-related hypoxemia and heart rate dynamics are associated with systemic inflammation in people living with HIV.Sleep & breathing = Schlaf & Atmung · 2026Article
- Cytokine Concentrations in Seminal Plasma and Blood in HIV Infection: Differential Modulation by Antiretroviral Therapy and Association with HIV RNA Levels and CD4International journal of general medicine · 2026Article
- Article
- The apparent interferon resistance of transmitted HIV-1 is possibly a consequence of enhanced replicative fitness.PLoS pathogens · 2022Article
- The role of IFN-γ production during retroviral infections: an important cytokine involved in chronic inflammation and pathogenesis.Revista do Instituto de Medicina Tropical de Sao Paulo · 2022Review
- The antiviral state has shaped the CpG composition of the vertebrate interferome to avoid self-targeting.PLoS biology · 2021Article
- P-Selectin Glycoprotein Ligand 1: A Potential HIV-1 Therapeutic Target.Frontiers in immunology · 2021Review
- A new cell line for assessing HIV-1 antibody dependent cellular cytotoxicity against a broad range of variants.Journal of immunological methods · 2020Article
- PSGL-1 inhibits HIV-1 infection by restricting actin dynamics and sequestering HIV envelope proteins.Cell discovery · 2020Article
- TRIM69 Inhibits Vesicular Stomatitis Indiana Virus.Journal of virology · 2019Article
- Proteomic profiling of HIV-1 infection of human CD4Nature microbiology · 2019Article
- Review
- Impact of Endemic Infections on HIV Susceptibility in Sub-Saharan Africa.Tropical diseases, travel medicine and vaccines · 2019Review
- Direct Antiviral Mechanisms of Interferon-Gamma.Immune network · 2018Review
- The aryl hydrocarbon receptor and interferon gamma generate antiviral states via transcriptional repression.eLife · 2018Article
- Interferon-Stimulated Gene (ISG)-Expression Screening Reveals the Specific Antibunyaviral Activity of ISG20.Journal of virology · 2018Article
- Article
- Interferon-Gamma-Mediated Osteoimmunology.Frontiers in immunology · 2018Review
- Fundamental properties of the mammalian innate immune system revealed by multispecies comparison of type I interferon responses.PLoS biology · 2017Article
- Inhibiting the Ins and Outs of HIV Replication: Cell-Intrinsic Antiretroviral Restrictions at the Plasma Membrane.Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Type I interferon (IFN) signaling engenders an antiviral state that likely plays an important role in constraining HIV-1 transmission and contributes to defining subsequent AIDS pathogenesis. Type II IFN (IFN-γ) also induces an antiviral state but is often primarily considered to be an immunomodulatory cytokine. We report that IFN-γ stimulation can induce an antiviral state that can be both distinct from that of type I interferon and can potently inhibit HIV-1 in primary CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.